Provider of cell engineering solutions for the development of next-generation cell-based therapies.
MaxCyte, Inc. is a global leader in the life sciences sector, specializing in the advancement and commercialization of cutting-edge cell therapies. The company is at the forefront of discovering, developing, and bringing to market next-generation cell therapies that have the potential to revolutionize medical treatments.
MaxCyte's product portfolio includes innovative technologies like ExPERT ATx, designed for static electroporation to facilitate transfection at small to medium scales. They also offer ExPERT STx, a flow electroporation system crucial for protein production, drug development, and the expression of therapeutic targets in cell-based assays. Additionally, their ExPERT GTx platform enables large-scale transfection for therapeutic applications, while ExPERT VLx supports very large volume cell engineering.
In addition to these advanced systems, MaxCyte provides disposable processing assemblies (PAs) that streamline the processing and electroporation of cells. These PAs are complemented by essential accessories such as electroporation buffer solutions and software protocols, ensuring comprehensive support for their cell engineering technologies.
Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte continues to drive innovation in the field of cell therapy. Their strategic location in Maryland, a hub for biotechnology, supports their pioneering research and development efforts. MaxCyte remains committed to leveraging its expertise to expand the boundaries of cell therapy and deliver impactful solutions to patients globally.